%0 Journal Article
%A Castells, Lluis
%A Rimola, Antoni
%A Manzardo, Christian
%A Valdivieso, Andres
%A Luis Montero, Jose
%A Barcena, Rafael
%A Abradelo, Manuel
%A Xiol, Xavier
%A Aguilera, Victoria
%A Salcedo, Magdalena
%A Rodriguez, Manuel
%A Bernal, Carmen
%A Suarez, Francisco
%A Antela, Antonio
%A Olivares, Sergio
%A del Campo, Santos
%A Laguno, Montserrat
%A Fernandez, Jose R.
%A de la Rosa, Gloria
%A Agueero, Fernando
%A Perez, Inaki
%A Gonzalez-Garcia, Juan
%A Esteban-Mur, Juan I.
%A Miro, Jose M.
%T Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study (vol 62, pg 92, 2015)
%D 2016
%@ 0168-8278
%U http://hdl.handle.net/10668/18823
%X Background & aims: The aim of this study was to evaluate the results of treatment with pegylated interferon and ribavirin for the recurrence of hepatitis C after liver transplantation in HCV/HIV-coinfected patients.Methods: This was a prospective, multicentre cohort study, including 78 HCV/HIV-coinfected liver transplant patients who received treatment for recurrent hepatitis C. For comparison, we included 176 matched HCV-monoinfected patients who underwent liver transplantation during the same period of time at the same centres and were treated for recurrent hepatitis C.Results: Antiviral therapy was discontinued prematurely in 56% and 39% (p = 0.016), mainly because of toxicity (22% and 11%, respectively; p=0.034). Sustained virological response (SVR) was achieved in 21% of the coinfected patients and in 36% of monoinfected patients (p = 0.013). For genotype 1, SVR rates were 10% and 33% (p = 0.002), respectively; no significant differences were observed for the other genotypes. A multivariate analysis based on the whole series identified HIV-coinfection as an independent predictor of lack of SVR (OR, 0.17; 95% CI, 0.06-0.42). Other predictors of SVR were donor age, pretreatment HCV viral load, HCV genotype, and early virological response. SVR was associated with a significant improvement in survival: 5-year survival after antiviral treatment was 79% for HCV/HIV-coinfected patients with SVR vs. 43% for those without (p = 0.02) and 92% vs. 60% in HCV-monoinfected patients (p < 0.001), respectively.Conclusions: The response to pegylated interferon and ribavirin was poorer in HCV/HIV-coinfected liver recipients, particularly those with genotype 1. However, when SVR was achieved, survival of coinfected patients increased significantly.
%K Antiviral treatment
%K HCV infection
%K HIV infection
%K Liver transplantation
%K Pegylated-interferon
%K Recurrence of hepatitis C
%K Ribavirin; Survival
%~